Literature DB >> 6722235

Lithium versus fluphenazine for prophylaxis in mainly schizophrenic schizo-affectives.

J A Mattes, D Nayak.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6722235

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN： 0006-3223            Impact factor:   13.382


× No keyword cloud information.
  6 in total

Review 1.  Schizoaffective disorder: a review of current research themes and pharmacological management.

Authors:  Joshua T Kantrowitz; Leslie Citrome
Journal:  CNS Drugs       Date:  2011-04       Impact factor: 5.749

2.  Lithium vs carbamazepine in the maintenance treatment of schizoaffective disorder: a randomised study.

Authors:  W Greil; W Ludwig-Mayerhofer; N Erazo; R R Engel; A Czernik; H Giedke; B Müller-Oerlinghausen; M Osterheider; G A Rudolf; H Sauer; J Tegeler; T Wetterling
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1997       Impact factor: 5.270

3.  Role of paliperidone extended-release in treatment of schizoaffective disorder.

Authors:  Carla M Canuso; Ibrahim Turkoz; Dong Jing Fu; Cynthia A Bossie
Journal:  Neuropsychiatr Dis Treat       Date:  2010-10-05       Impact factor: 2.570

Review 4.  Fluphenazine (oral) versus placebo for schizophrenia.

Authors:  Hosam E Matar; Muhammad Qutayba Almerie; Stephanie Sampson
Journal:  Cochrane Database Syst Rev       Date:  2013-07-17

Review 5.  Lithium for schizophrenia.

Authors:  Stefan Leucht; Bartosz Helfer; Markus Dold; Werner Kissling; John J McGrath
Journal:  Cochrane Database Syst Rev       Date:  2015-10-28

Review 6.  Fluphenazine (oral) versus placebo for schizophrenia.

Authors:  Hosam E Matar; Muhammad Qutayba Almerie; Stephanie J Sampson
Journal:  Cochrane Database Syst Rev       Date:  2018-06-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.